The benefits of semaglutide: what the evidence actually shows

What semaglutide actually does to appetite and weight

The question most people are really asking is: will it work for me? That starts with understanding the mechanism. Semaglutide mimics GLP-1, a gut hormone released after eating. When you inject it once weekly, it signals to the brain that you are full, slows the rate at which the stomach empties, and reduces the drive to eat between meals. This is not a stimulant or a fat-blocker, it works with your body's own signalling pathways.

The practical result, for most people in the clinical trials, was a substantially reduced appetite within the first few weeks. The STEP 1 trial (1,961 adults with obesity or overweight plus a weight-related condition, no diabetes, 68 weeks) recorded an average weight reduction of approximately 15% in the semaglutide group compared with around 2.4% in the placebo group. Roughly one in three participants lost more than 20% of their starting weight. These figures come from a controlled research setting; individual results vary, and a prescriber's assessment considers your whole health picture, not just your BMI.

One misconception worth setting aside gently: semaglutide is sometimes described as a shortcut that does the work for you. Participants in every trial made dietary and activity changes alongside the medicine. The drug reduces the friction; the lifestyle work still happens. The NHS medicines page for semaglutide describes this clearly.

Benefits that go beyond weight loss

Weight reduction produces a cascade of secondary changes that are worth knowing about, because for many people they are the more pressing reason to consider treatment. In the STEP trials, participants who lost significant weight also showed, on average, reductions in systolic blood pressure, improvements in fasting blood-glucose levels, and improvements in cholesterol profiles. If you want a fuller picture of what these wider benefits of taking semaglutide look like in practice, we cover them in detail separately.

Semaglutide holds a separate UK licence for reducing the risk of major cardiovascular events in eligible adults, a distinct authorisation from its weight-management licence. It also received conditional MHRA approval in July 2026 for a form of fatty liver disease. These indications are not the reason most people search for Wegovy, and at nume we prescribe it for weight management; but knowing the breadth of the evidence base is part of making an informed decision.

The benefits people describe in practice often include better energy, improved sleep (particularly relevant for those with obesity-related sleep apnoea) and a changed relationship with food. Those are harder to quantify than a trial percentage, but they matter. Our clinical team hears this regularly from patients who have been on treatment for several months.

Who is likely to benefit, and who should pause before deciding

Semaglutide (Wegovy) is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE recommends semaglutide (TA875) within specialist weight management services, with a maximum recommended treatment duration of two years.

The benefits are clearest for people who meet the licensed criteria and take the medicine alongside genuine dietary and activity changes, and our page on the specific semaglutide benefits for weight loss goes into more depth on what the evidence shows for different starting points. If less than 5% weight loss has occurred after six months at the maintenance dose, continuing is reviewed, the evidence suggests the medicine is working best for those who respond in this window.

There are situations where semaglutide is not appropriate: pregnancy, breastfeeding, or actively trying to conceive; anyone under 18; and people with a history of certain conditions including medullary thyroid carcinoma or a personal or family history of MEN2. The full contraindications are worth reading before deciding. Specific considerations for women (including interactions with oral contraceptives) are covered separately.

Weighing the benefits against the side-effect profile

No medicine's benefit picture is complete without the side-effect side. For semaglutide, the most commonly reported effects are gastrointestinal: nausea, diarrhoea, constipation, and indigestion. These are most noticeable in the weeks after starting or after a dose increase, and for most people they settle as the body adjusts. They are rarely a reason to stop, but they are real and worth anticipating.

Rarer but serious effects include acute pancreatitis, the MHRA highlighted this as a known risk for GLP-1 medicines and advises seeking urgent help for severe, persistent stomach pain that spreads to the back. Gallbladder problems and, in people with diabetes, changes in diabetic eye disease are also flagged in prescribing guidance. Anyone experiencing these symptoms should contact a healthcare professional promptly; side effects can also be reported via the MHRA's Yellow Card scheme.

The overall benefit-to-risk balance for most eligible adults is what led NICE and the MHRA to support semaglutide's use. Understanding that balance (not just the weight-loss headline) is what an honest assessment looks like. If you are weighing up cost as part of this decision, our Wegovy price comparison page sets out what private treatment typically involves in the UK.